StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Cancidas (caspofungin, legacy) by Year

Cancidas (caspofungin, legacy) — Worldwide reported growth YoY (%) (%)

Merck Cancidas (caspofungin, legacy): -14.0% in FY2020, up 10.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2020
-14.0%
Period ended Dec 31, 2020
Change on a year earlier
+10.0 pts
-24.0% in FY2019
History
4 years
Since FY2017
Sources
4
Documents cited below

Where the FY2020 figure comes from

“|| Cancidas | 55 | 43 | 50 | 65 | 213 | 61 | 67 | 62 | 58 | 249 | 13 | 11 | -14 | -13”

Source: Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCancidas (caspofungin, legacy) — Worldwide reported growth YoY (%) (%)Year on yearSource
FY2020Dec 31, 2020-14.0%+10.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2019Dec 31, 2019-24.0%-1.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 2018-23.0%+1.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 2017-24.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Cancidas (caspofungin, legacy) (%), annual FY2017–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cancidas-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.